Welichem Obtains Approval for Phase IIa Clinical Trial on Eczema
Welichem Biotech Inc. announced that Health Canada approved the Company's Clinical Trial Application (CTA) to begin a Phase IIa Clinical Trial of its anti-inflammatory drug candidate, WBI-1001, on atopic dermatitis (a type of eczema).
The Company will initiate its Phase IIa Clinical Trial of WBI-1001 as a topical cream application against atopic dermatitis in the coming months. Atopic dermatitis is normally treated topically with corticosteroids or other immune-suppressors, and these treatments often result in adverse effects after long-term use. WBI-1001 has been developed as a more effective and tolerable topical treatment of this chronic disease.
The Company has completed a Phase I Clinical Trial of this drug candidate on psoriasis, and the clinical data on its safety and efficacy in the Trial should be available by the end of April this year. A Phase II study to confirm and explore its safety and efficacy on psoriasis is planned for mid-2008. Meantime, the Company continues on its rigorous research and development schedule.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01 - Financing secures further clinical trials and the supply of material for the treatment of COVID-19 patients
NovogeneAIT Singapore and the Genome Institute of Singapore forge Public-Private Partnership - Establishing whole genome sequencing centre in Singapore
Gene that influences the ability to remember faces
Estación_de_Fotobiología_Playa_Unión

E. coli bacteria's defense secret revealed
Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence

Faecal Pollution: DNA Uncovers Culprit - CSI and forensics can be used to uncover not only serial killers but also the cause of water pollution
Chinese_Mental_Health_Association
Catalent Invests $7.3 Million in Italy - Expands Softgel Encapsulation and Packaging Capabilities in Support of Consumer Health
